Answers are grounded in this paper and cite their sources.
Patients treated with mepolizumab demonstrated progressive and sustained long-term, real-world reductions in exacerbation frequency, OCS dependency, and exacerbation-related HCRU and costs over 4 years.
No takes yet. Share an insight, caveat, or question.
Moore et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: